OAT1 and OAT3: Targets of drug–drug interaction between entecavir and JBP485
Authors:
- Changyuan WangCWChangyuan Wang
- Qiang MengQMQiang Meng
- Qi LiuQLQi Liu
- Huijun SunHSHuijun Sun
- Jinyong PengJPJinyong Peng
- Xiaochi MaXMXiaochi Ma
- Taiichi KakuTKTaiichi Kaku
- Kexin LiuKLKexin Liu
- 1 March 2013
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 48 (4-5) , 650-657
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study resultsInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2012
- High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis BClinical and Molecular Hepatology, 2012
- In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug–drug interaction with methotrexateEuropean Journal of Pharmaceutical Sciences, 2011
- LC–ESI-MS/MS method for the quantification of entecavir in human plasma and its application to bioequivalence studyJournal of Chromatography B, 2011
- Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactionsBiopharmaceutics & Drug Disposition, 2011
- Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agentsJournal of Medical Virology, 2011
- Pharmacokinetics and Mechanism of Intestinal Absorption of JBP485 in RatsDrug Metabolism and Pharmacokinetics, 2010
- Side effects of long-term oral antiviral therapy for hepatitis B #Hepatology, 2009
- Fluorescence-Based Assay for the Interaction of Small Molecules with the Human Renal Organic Anion Transporter 1Analytical Biochemistry, 2000